PRCH-1

PER·Percheron Therapeutics·Solid tumours (ATR kinase inhibitor)·Phase 1·[ TODO: fill in ]

Plain-language Brief

The trial in plain terms

The disease: Solid tumours is a broad category covering cancers that form discrete masses in organs and tissues, as distinct from blood cancers. Many solid tumours develop resistance to standard chemotherapy or targeted agents, leaving patients with limited options after initial treatment fails. The specific tumour types and treatment settings being targeted by PRCH-1 are not stated in the available data.
What the asset is trying to do: PRCH-1 is described as an inhibitor of ATR (Ataxia Telangiectasia and Rad3-related), a protein kinase that plays a central role in the DNA damage response pathway inside cells. By blocking ATR, this class of drug aims to impair a tumour cell's ability to repair damaged DNA, potentially making it more vulnerable to cell death. How PRCH-1 differs structurally or pharmacologically from other ATR inhibitors in development is not stated in the available data.
What the trial is measuring, and why it matters: The specific endpoints and trial design for the PRCH-1 Phase 1 study in solid tumours are not available in the data provided. Phase 1 oncology trials typically assess safety, tolerability, and the recommended dose for further study, but the registered endpoints for this specific trial have not been disclosed here.
Efficacy benchmarks in this setting: No registered trial record for PRCH-1 in solid tumours has been identified in the data provided, so no efficacy benchmarks for this specific setting can be matched. Among approved ATR inhibitors, has demonstrated in (per ). Any early-stage figures generated by PRCH-1 would not be statistically comparable to data from larger, randomised studies of approved agents.
Commercial context: No regulatory approvals for PRCH-1 have been disclosed, and no partnering or licensing transactions involving this asset are noted in the available announcements. The company's recent announcements reference a separate asset, HMBD-002, with preclinical data presented at ASCO 2026 (per ASX announcement 2026-06-01), and a capital raise completed in April 2026 (per ASX announcements 2026-04-14). Whether PRCH-1 or HMBD-002 is the company's lead asset is not stated in the available data.

Sources for this brief (3)

ClinicalTrials.gov — search ATR inhibitor solid tumour trials · U.S. National Library of Medicine · accessed 15 June 2026
Percheron Therapeutics ASX Announcements · Australian Securities Exchange · accessed 15 June 2026
Quarterly Activities Report and Appendix 4C — April 2026 · Percheron Therapeutics / ASX · accessed 15 June 2026

Trial Design

Design summary

Phase: Phase 1
Design type: [ TODO: fill in ]
Primary endpoint: [ TODO: fill in ]
Key secondary endpoints: [ TODO: fill in ]
Enrolment target: [ TODO: fill in ]
Current enrolment status: [ TODO: fill in ]
Sites: [ TODO: fill in ]
Expected readout window: [ TODO: fill in ]

Asset Track Record

Did PER deliver against its own guidance?

Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.

30 May 2026conference presentationHMBD-002 preclinical data at ASCO 2026hitASX ↗
29 May 2026financingProposed issue of securities - PERhitsrc ASX ↗
30 Mar 2026data readoutNew HMBD-002 Preclinical Data to be Presented at ASCOhit · positivesrc

Class Catalyst Calendar

What's landed, what's next for PRCH-1 and peers

PRCH-1's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for PRCH-1.

ConferenceAACR Annual Meeting 2026· ChicagoApr 2026
ConferenceASCO Annual Meeting 2026· ChicagoMay 2026
Today
ConferenceESMO Congress 2026· MadridSept 2026

Trial design comparison

How PRCH-1 reads against active peer trials

Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.

Trial	Sponsor	Class	Phase / Line	Design	Primary endpoint	Dosing	Key eligibility	n
PRCH-1	Percheron Therapeutics	Kinase Inhibitor	Phase 1[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	[ TODO: fill in ]	0
9-ING-41 in Patients With Advanced Cancers	Actuate Therapeutics Inc.	—

Competitor Landscape

Competing programmes by mechanism and phase

Read-across commentary attached per trial. Phase ordering preserved within each group.

OtherASX peers ›

6 activeexpand ›

AI
9-ING-41 in Patients With Advanced Cancers
Phase 2
Actuate Therapeutics Inc.·Active, not recruiting·Primary completion 1 June 2026·NCT03678883
NC
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
PHASE1/PHASE2

Curated Commentary

Third-party coverage(none curated yet)

expand ›

External analyst notes, journalism, and industry commentary cited with attribution.

No third-party coverage curated for PRCH-1 yet. Broker coverage of Percheron Therapeutics is thin; named analyst notes will appear here as they become available. For now, see the company's ASX announcements and the linked sponsor / class sources elsewhere on this page.